Loading
Loading
Growth Hormone & Secretagogues · 10mg + 10mg
Choose dose
Janoshik-tested · 10 vials per kit
CJC-1295 + Ipamorelin is a research blend of CJC-1295 without DAC (Mod GRF 1-29) 10mg and Ipamorelin 10mg (20mg total per vial) studied in preclinical research for synergistic growth hormone axis regulation. Mod GRF 1-29 has a short half-life (~30 minutes) and stimulates a pulsatile GHRH-receptor signal; Ipamorelin selectively stimulates GH secretion at the pituitary level via the ghrelin receptor. Research has examined their mechanistically complementary, dual-pathway approach for studying synchronised growth hormone pulses and feedback regulation.
Blended compound — purity note
Peptide blends are not tested for combined purity as a single compound. However, every component is sourced from the same supplier as our individual peptide products, all of which carry valid Janoshik Analytical COAs. Those certificates apply equally to the same peptides in this blend. View individual COAs →
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties · CJC-1295 No DAC
Chemical Properties · Ipamorelin
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
CJC-1295 No DAC
Modified GRF(1-29)
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a 29-amino-acid analog of GHRH(1-44) stabilised by four amino acid substitutions (positions 2, 8, 15, and 27) but without the albumin-binding Drug Affinity Complex. This gives a half-life of ~30 minutes — substantially longer than endogenous GHRH (minutes) but far shorter than CJC-1295 DAC (days), producing discrete GH pulses rather than sustained GH elevation.
Acts on GHRH receptors (GHRHr) on anterior pituitary somatotrophs to stimulate GH synthesis and release, then clears quickly — mimicking a single physiological GHRH pulse. This pulsatile pattern is considered more biomimetic than sustained GH elevation from DAC forms. It is typically administered in combination with a ghrelin mimetic (Ipamorelin, GHRP-2) — the two receptor pathways (cAMP/PKA via GHRHr + IP3/PKC via GHS-R1a) are complementary, producing synergistic GH pulses 2-5× larger than either alone.
Modified GRF 1-29 is the most commonly studied short-acting GHRH analog in combination GH secretagogue protocols. Research encompasses GH-axis stimulation, body composition, recovery, sleep-associated GH release, and age-related GH decline. Its pulsatile GH release profile may better preserve hypothalamic-pituitary feedback compared to sustained-release forms.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
